Investigational drug · Phase 3
H1 receptor antagonist
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
249
Any phase or sponsor naming "H1 receptor antagonist"
First trial start
2024
Jun 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "H1 receptor antagonist", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lung Neoplasm Malignant
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Non-small Cell Lung Cancer (NSCLC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "H1 receptor antagonist" as an intervention, largest first.
Consorci Sanitari de TerrassaAcademic, hospital or other
NCT05504057 · 140,660 participants (planned) · Start Mar 1, 2020 · Primary completion Jan 19, 2025
Drug: Antihistamine; Amantadine · For: COVID-19
Sites: Terrassa, Spain · 2 sites in all
- Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.Pivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT04688736 · 6,642 participants (planned) · Start Jan 1, 2021 · Primary completion Dec 31, 2026
Drug: Placebo; Chlorpheniramine · For: Allergic Transfusion Reaction
Sites: Hefei, China; Zhoukou, China; Tai’an, China · 4 sites in all
Consorci Sanitari de TerrassaAcademic, hospital or other
NCT04367883 · 3,000 participants (planned) · Start Mar 1, 2020 · Primary completion Jan 19, 2025
Drug: Antihistamine; Amantadine and 2 more · For: COVID19; Influenza Vaccination; ACE Inhibitors and 3 more
Sites: Terrassa, Spain
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06393374 · 1,530 participants (planned) · Start Jun 24, 2024 · Primary completion Dec 16, 2030
Drug: Pembrolizumab; Sacituzumab tirumotecan and 1 more · For: Triple-Negative Breast Cancer
Sites: Mobile, Alabama; Chandler, Arizona; Fountain Valley, California · 317 sites in all
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07216703 · 1,023 participants (planned) · Start Jan 19, 2026 · Primary completion Oct 29, 2031
Drug: Pembrolizumab; Sacituzumab Tirumotecan and 5 more · For: Cervical Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Irvine, California · 189 sites in all
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06841354 · 1,000 participants (planned) · Start Mar 16, 2025 · Primary completion May 18, 2030
Drug: Sacituzumab tirumotecan; Pembrolizumab and 5 more · For: Triple Negative Breast Neoplasms
Sites: Mobile, Alabama; Chandler, Arizona; Duarte, California · 285 sites in all
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Pivotal-lookingActive, not recruiting
Celldex TherapeuticsIndustry
NCT06455202 · 976 participants · Start Jul 19, 2024 · Primary completion Aug 4, 2026
Drug: barzolvolimab; Matching placebo · For: Chronic Spontaneous Urticaria
Sites: Cullman, Alabama; Litchfield Park, Arizona; Scottsdale, Arizona · 245 sites in all
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaPivotal-lookingActive, not recruiting
Celldex TherapeuticsIndustry
NCT06445023 · 963 participants · Start Jul 11, 2024 · Primary completion Aug 12, 2026
Drug: barzolvolimab; Matching placebo · For: Chronic Spontaneous Urticaria
Sites: Birmingham, Alabama; Fountain Valley, California; Inglewood, California · 235 sites in all
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07318558 · 900 participants (planned) · Start Feb 16, 2026 · Primary completion Feb 25, 2033
Drug: Sacituzumab tirumotecan; Bevacizumab and 1 more · For: Ovarian Neoplasms; Ovarian Cancer
Sites: Birmingham, Alabama; La Jolla, California; Newport Beach, California · 178 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Understanding the Anti-inflammatory Activity of Second-Generation H1 Antihistamines.
García de la Fuente A, Badía-Santolaria C, Carreras-Katcheff S, et al. · J Investig Allergol Clin Immunol 2026
- Ebastine attenuates DSS-induced ulcerative colitis via modulation of NF-κB, oxidative stress and pro-inflammatory cytokines: evidence for antihistamine repurposing.
Vanjari A, Shinde S, Bhange A, et al. · Inflammopharmacology 2026
- Association between prophylactic desloratadine use and docetaxel-induced skin toxicities in patients with early-stage breast cancer: an inverse probability-weighted retrospective cohort study.
Makihara K, Kongo K, Motomura K, et al. · Support Care Cancer 2026
- Olopatadine in Seasonal Allergic Conjunctivitis: Efficacy, Ocular Surface Safety, and Practical Considerations for Preservative-Free Multidose Therapy.
Ciprandi G · J Clin Med 2026
- ADAM17 inhibition by the common antihistamine drug fexofenadine dampens soluble proinflammatory TNF-α release.
Puthiyottil S, Jose D, Kuriakose N, et al. · Biochem Pharmacol 2026
- Neuropsychiatric adverse effects of antihistamine: A nationwide data-based epidemiological study in South Korea.
Kim JY, Shin DW, Kim Z, et al. · Asian Pac J Allergy Immunol 2026
Also in development for Lung Neoplasm Malignant
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- MK-1084CalderasibPhase 38 trials
Merck & Co. · Non-small Cell Lung Cancer, Colon Adenocarcinoma, Rectal Adenocarcinoma
- H2 receptor antagonistPhase 34 trials
Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.